In summary, our findings demonstrated that A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block membrane translocation of “eat-me” signal, which may represent a novel predictive biomarker for selecting CRC patients who are most likely to benefit from ICI therapy alone or its combination with other anticancer treatment. This evidence concerns the gene STC1 and colorectal cancer.